RefleXion receives breakthrough device designation for lung cancer treatment

RefleXion Medical

1 December 2021 - RefleXion Medical today announced that the U.S. FDA has granted the company breakthrough device designation for its biology guided radiotherapy for use in treating lung tumours. 

The breakthrough potential of biology guided radiotherapy lies in its ability to detect and then immediately treat moving tumours.

Read RefleXion Medical press release

Michael Wonder

Posted by:

Michael Wonder